AU2009313357B2 - Monoclonal antibodies to fibroblast growth factor receptor 2 - Google Patents

Monoclonal antibodies to fibroblast growth factor receptor 2 Download PDF

Info

Publication number
AU2009313357B2
AU2009313357B2 AU2009313357A AU2009313357A AU2009313357B2 AU 2009313357 B2 AU2009313357 B2 AU 2009313357B2 AU 2009313357 A AU2009313357 A AU 2009313357A AU 2009313357 A AU2009313357 A AU 2009313357A AU 2009313357 B2 AU2009313357 B2 AU 2009313357B2
Authority
AU
Australia
Prior art keywords
mab
gal
fgfr2
human
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2009313357A
Other languages
English (en)
Other versions
AU2009313357A1 (en
Inventor
Kyung Jin Kim
Hangil Park
Maximiliano Vasquez
Wei-Meng Zhao
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Galaxy Biotech LLC
Original Assignee
Galaxy Biotech LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Galaxy Biotech LLC filed Critical Galaxy Biotech LLC
Publication of AU2009313357A1 publication Critical patent/AU2009313357A1/en
Assigned to GALAXY BIOTECH, LLC reassignment GALAXY BIOTECH, LLC Amend patent request/document other than specification (104) Assignors: KIM, KYUNG JIN
Application granted granted Critical
Publication of AU2009313357B2 publication Critical patent/AU2009313357B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/5759—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds localised on the membrane of tumour or cancer cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/71—Assays involving receptors, cell surface antigens or cell surface determinants for growth factors; for growth regulators

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AU2009313357A 2008-11-07 2009-11-06 Monoclonal antibodies to fibroblast growth factor receptor 2 Active AU2009313357B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US11268608P 2008-11-07 2008-11-07
US61/112,686 2008-11-07
US16487009P 2009-03-30 2009-03-30
US61/164,870 2009-03-30
PCT/US2009/063647 WO2010054265A2 (en) 2008-11-07 2009-11-06 Monoclonal antibodies to fibroblast growth factor receptor 2

Publications (2)

Publication Number Publication Date
AU2009313357A1 AU2009313357A1 (en) 2010-05-14
AU2009313357B2 true AU2009313357B2 (en) 2015-06-11

Family

ID=42153600

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2009313357A Active AU2009313357B2 (en) 2008-11-07 2009-11-06 Monoclonal antibodies to fibroblast growth factor receptor 2

Country Status (20)

Country Link
US (8) US8101723B2 (enExample)
EP (4) EP2365828B1 (enExample)
JP (8) JP5627591B2 (enExample)
KR (1) KR101699432B1 (enExample)
CN (1) CN102131524B (enExample)
AU (1) AU2009313357B2 (enExample)
BR (1) BRPI0917315B8 (enExample)
CA (3) CA3287843A1 (enExample)
DK (3) DK3290052T3 (enExample)
ES (3) ES2646168T3 (enExample)
HR (2) HRP20171640T1 (enExample)
HU (1) HUE035700T2 (enExample)
LT (2) LT3290052T (enExample)
MX (1) MX2011000455A (enExample)
NO (1) NO2842573T3 (enExample)
PL (3) PL2842573T3 (enExample)
PT (3) PT2365828E (enExample)
RU (1) RU2546254C9 (enExample)
SI (2) SI3290052T1 (enExample)
WO (1) WO2010054265A2 (enExample)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009100105A2 (en) * 2008-02-04 2009-08-13 Attogen Inc. Inhibitors of oncogenic isoforms and uses thereof
US9260525B2 (en) 2008-02-04 2016-02-16 Xiao-Jia Chang Antibody molecules to oncogenic isoforms of fibroblast growth factor receptor-2 and uses thereof
WO2012021841A2 (en) * 2010-08-12 2012-02-16 Attogen Inc. Antibody molecules to oncogenic isoforms of fibroblast growth factor receptor-2 and uses thereof
DK3290052T3 (da) 2008-11-07 2020-02-03 Galaxy Biotech Llc Monoklonale antistoffer mod fibroblastvækstfaktorreceptor 2
CA2800311A1 (en) 2010-05-11 2011-11-17 Aveo Pharmaceuticals, Inc. Anti-fgfr2 antibodies
JP6400470B2 (ja) 2011-05-16 2018-10-03 ジェネロン（シャンハイ）コーポレイション リミテッド 多重特異性Ｆａｂ融合タンパク質および使用法
AR088941A1 (es) 2011-11-23 2014-07-16 Bayer Ip Gmbh Anticuerpos anti-fgfr2 y sus usos
MX2014007121A (es) * 2011-12-14 2014-09-04 Seattle Genetics Inc Nuevos conjugados de principio activo-ligante (adc) y su uso.
MX360056B (es) 2012-03-08 2018-10-19 Janssen Vaccines & Prevention Bv Moléculas de unión humanas que pueden unirse a los virus de la influenza b y neutralizarlos, y sus usos.
AU2013247645B2 (en) * 2012-04-09 2019-02-14 Daiichi Sankyo Company, Limited Anti-FGFR2 antibody
WO2014089193A1 (en) * 2012-12-04 2014-06-12 Aveo Pharmaceuticals, Inc. Anti-fgfr2 antibodies
CN104995512A (zh) * 2012-12-21 2015-10-21 詹森生物科技公司 用于可溶性成纤维细胞生长因子受体的灵敏的多重免疫测定
CN103145843B (zh) * 2013-02-20 2014-10-29 暨南大学 抗成纤维细胞生长因子受体的单链抗体
JP2016510751A (ja) 2013-03-06 2016-04-11 ジェネンテック， インコーポレイテッド 抗がん剤耐性を治療及び予防する方法
MX374785B (es) * 2013-08-01 2025-03-06 Five Prime Therapeutics Inc Anticuerpos anti-fgfr2iiib afucosilados.
CN105792844B (zh) * 2013-10-08 2021-03-02 第一三共株式会社 抗fgfr2抗体和另一药剂的组合
CN103757026B (zh) * 2013-12-20 2017-04-05 广州圣露生物技术有限公司 FGFR2b胞外段的基因序列、多肽及其应用
WO2015191986A1 (en) 2014-06-13 2015-12-17 Genentech, Inc. Methods of treating and preventing cancer drug resistance
CN104231079A (zh) * 2014-09-12 2014-12-24 暨南大学 一种靶向bFGF高亲和力受体结合位点的抗体及其应用
JP6887944B2 (ja) * 2015-04-08 2021-06-16 第一三共株式会社 抗ｆｇｆｒ２抗体と他剤を含む組成物
WO2016171107A1 (ja) * 2015-04-20 2016-10-27 第一三共株式会社 Ｆｇｆｒ２の検出
RU2638457C2 (ru) * 2015-09-28 2017-12-13 Общество С Ограниченной Ответственностью "Онкомакс" Антитела, специфически связывающие рецептор 1 типа фактора роста фибробластов, применение антител для лечения онкологического заболевания, способ получения антител
SG10201913538VA (en) * 2015-11-23 2020-02-27 Five Prime Therapeutics Inc Fgfr2 inhibitors alone or in combination with immune stimulating agents in cancer treatment
WO2017157305A1 (en) 2016-03-15 2017-09-21 Generon (Shanghai) Corporation Ltd. Multispecific fab fusion proteins and use thereof
US10093731B2 (en) 2017-02-24 2018-10-09 Kindred Biosciences, Inc. Anti-IL31 antibodies for veterinary use
DK3624837T3 (da) 2017-05-16 2025-09-29 Five Prime Therapeutics Inc Anti-fgfr2-antistoffer i kombination med kemoterapeutiske midler til kræftbehandling
CN118085076A (zh) 2017-06-02 2024-05-28 埃博灵克斯股份有限公司 结合聚集蛋白聚糖的免疫球蛋白
WO2019084067A1 (en) * 2017-10-24 2019-05-02 Magenta Therapeutics, Inc. ANTI-CD117 ANTIBODIES AND METHODS OF USE
EP3700568A4 (en) 2017-10-24 2021-11-10 Magenta Therapeutics, Inc. COMPOSITIONS AND METHODS FOR DEPLOYING CD117 + CELLS
US10882915B2 (en) 2017-10-24 2021-01-05 Magenta Therapeutics, Inc. Compositions and methods for the depletion of CD117+ cells
EP3847196A4 (en) 2018-09-07 2023-01-04 ITabMed (HK) Limited BISPECIFIC ANTIGEN BINDING PROTEINS AND USES THEREOF
PE20211213A1 (es) 2018-10-05 2021-07-05 Five Prime Therapeutics Inc Formulaciones de anticuerpos anti-fgfr2
WO2020132810A1 (en) 2018-12-24 2020-07-02 Generon (Shanghai) Corporation Ltd. Multispecific antigen binding proteins capable of binding cd19 and cd3, and use thereof
JP7671275B2 (ja) 2019-08-29 2025-05-01 エランコ・ユーエス・インコーポレイテッド 動物用の抗ｉｌ３１抗体
AR120884A1 (es) * 2019-12-24 2022-03-23 Dizal Jiangsu Pharmaceutical Co Ltd Anticuerpos anti-fgfr2b
CN114846029A (zh) * 2019-12-24 2022-08-02 迪哲(江苏)医药股份有限公司 新颖抗fgfr2b抗体
AU2021284297A1 (en) * 2020-06-03 2023-02-02 Dana-Farber Cancer Institute, Inc. Antagonistic biparatopic antibodies that specifically bind fibroblast growth factor receptor 2 and methods of using same
US11866502B2 (en) 2020-10-22 2024-01-09 Regeneron Pharmaceuticals, Inc. Anti-FGFR2 antibodies and methods of use thereof
EP4273166A4 (en) * 2020-12-29 2025-04-16 Shenzhen Forward Pharmaceuticals Co., Limited ANTI-FGFR2 ANTIBODIES AND USE THEREOF
US20250277041A1 (en) * 2021-10-08 2025-09-04 Shenzhen Forward Pharmaceuticals Co., Limited Anti-fgfr2 adcc enhanced antibody and use thereof
TW202342527A (zh) 2022-02-25 2023-11-01 美商安進公司 鱗狀非小細胞肺癌之治療
CN120418288A (zh) * 2022-09-30 2025-08-01 思康睿奇(上海)药业有限公司 FGFR2b抗体及其用途
CN118852431A (zh) * 2023-04-28 2024-10-29 武汉人福创新药物研发中心有限公司 抗FGFR2b单抗
CN118994393A (zh) * 2023-05-19 2024-11-22 广东东阳光药业股份有限公司 一种抗fgfr2抗体及其应用
WO2024255756A1 (zh) * 2023-06-13 2024-12-19 南京维立志博生物科技股份有限公司 基于共同轻链产生双特异性抗体的方法
WO2025130905A1 (zh) * 2023-12-18 2025-06-26 山东先声生物制药有限公司 抗FGFR2b抗体-药物缀合物及其应用
WO2025218662A1 (zh) * 2024-04-16 2025-10-23 杭州中美华东制药有限公司 抗成纤维细胞生长因子受体2b的抗体及其用途
TW202547875A (zh) * 2024-05-09 2025-12-16 大陸商正大天晴藥業集團股份有限公司 靶向成纖維細胞生長因子受體2IIIb的抗體及其應用
CN121319178A (zh) * 2024-07-02 2026-01-13 安博泰克药业有限公司 特异性结合FGFR2b的抗体及其与药物的缀合物

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070248605A1 (en) * 2003-12-19 2007-10-25 Five Prime Therapetutics, Inc. Fibroblast Growth Factor Receptors 1,2,3, and 4 as Targets for Therapeutic Intervention
WO2007134210A2 (en) * 2006-05-12 2007-11-22 Genentech, Inc. Methods and compositions for the diagnosis and treatment of cancer
WO2008118877A2 (en) * 2007-03-23 2008-10-02 The Translational Genomics Research Institute Method of diagnosing, classifying and treating endometrial cancer and precancer

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3101690B2 (ja) 1987-03-18 2000-10-23 エス・ビィ・２・インコーポレイテッド 変性抗体の、または変性抗体に関する改良
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
WO1991000916A2 (en) * 1989-07-06 1991-01-24 The Regents Of The University Of California Receptors for fibroblast growth factors
EP1690935A3 (en) 1990-01-12 2008-07-30 Abgenix, Inc. Generation of xenogeneic antibodies
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
US5863888A (en) * 1990-07-06 1999-01-26 Rhone-Poulenc Rorer Pharmaceuticals Inc. Human Bek Fibroblast growth factor receptor
ES2139598T3 (es) 1990-07-10 2000-02-16 Medical Res Council Procedimientos para la produccion de miembros de parejas de union especifica.
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
JPH07503132A (ja) 1991-12-17 1995-04-06 ジェンファーム　インターナショナル，インコーポレイティド 異種抗体を産生することができるトランスジェニック非ヒト動物
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
US6066718A (en) 1992-09-25 2000-05-23 Novartis Corporation Reshaped monoclonal antibodies against an immunoglobulin isotype
NZ275711A (en) 1993-10-14 1998-03-25 Immunex Corp Monoclonal antibodies and binding proteins which bind to human fas antigen (nerve growth factor/tumour necrosis factor receptor type)
US5834597A (en) 1996-05-20 1998-11-10 Protein Design Labs, Inc. Mutated nonactivating IgG2 domains and anti CD3 antibodies incorporating the same
WO1997048813A2 (en) 1996-06-18 1997-12-24 The United States Of America, Represented By The Secretary, Department Of Health And Human Services Fibroblast growth factor receptor activating gene 1 (frag1). fgfr2-frag1 fusions
US20030143676A1 (en) * 1999-03-25 2003-07-31 Genesis Research And Development Corporation Limited Fibroblast growth factor receptors and methods for their use
EP1179541B1 (en) * 1999-04-28 2004-06-16 Board Of Regents, The University Of Texas System Compositions and methods for cancer treatment by selectively inhibiting VEGF
JP2001302699A (ja) 2000-04-17 2001-10-31 Nichirei Corp ヒトｋｇｆｒに対する抗体
US20020115603A1 (en) 2000-06-22 2002-08-22 Chiron Corporation Methods and compositions for the treatment of peripheral artery disease
KR100945108B1 (ko) * 2001-06-13 2010-03-02 젠맵 에이/에스 표피 성장 인자 수용체 (ｅｇｆｒ)에 대한 인간모노클로날 항체
IL159177A0 (en) 2001-06-20 2004-06-01 Prochon Biotech Ltd Antibodies that block receptor protein tyrosine kinase activation, methods of screening for and uses thereof
AU2002368077B2 (en) 2001-07-12 2010-03-04 Jefferson Foote Super humanized antibodies
ES2363765T3 (es) 2002-01-31 2011-08-16 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Agonistas de fgfr.
KR100493460B1 (ko) * 2002-08-29 2005-06-07 재단법인서울대학교산학협력재단 암 세포에서 발현되는 ｆｇｆｒ2 이성체
US7220410B2 (en) 2003-04-18 2007-05-22 Galaxy Biotech, Llc Monoclonal antibodies to hepatocyte growth factor
EA015363B1 (ru) 2003-07-18 2011-06-30 Эмджен Инк. Агенты, специфически связывающие фактор роста гепатоцитов, и их применение
EP1773305A2 (en) * 2004-05-25 2007-04-18 Yale University Corporation Method for treating skeletal disorders resulting from fgfr malfunction
US7890267B2 (en) 2006-03-31 2011-02-15 Ordway Research Institute Prognostic and diagnostic method for cancer therapy
AR059922A1 (es) 2006-04-01 2008-05-07 Galaxy Biotech Llc Anticuerpos monoclonales humanizados para el factor de crecimiento de hepatocitos
US7649083B2 (en) 2006-06-02 2010-01-19 Aveo Pharmaceuticals, Inc. Hepatocyte growth factor (HGF) binding antibody
MX2008015138A (es) 2006-06-02 2009-01-28 Aveo Pharmaceuticals Inc Proteinas de union al factor de crecimiento de hepatocitos (fch).
US8101721B2 (en) 2006-06-15 2012-01-24 Fibron Ltd. Antibodies blocking fibroblast growth factor receptor activation and methods of use thereof
HRP20160082T1 (hr) 2006-09-29 2016-02-26 Oncomed Pharmaceuticals, Inc. Sastavi i postupci za dijagnosticiranje i lijeäśenje raka
EP2094733A1 (en) * 2006-11-03 2009-09-02 U3 Pharma GmbH Fgfr4 antibodies
WO2009052830A1 (en) 2007-10-22 2009-04-30 Genmab A/S Novel antibody therapies
WO2009100105A2 (en) 2008-02-04 2009-08-13 Attogen Inc. Inhibitors of oncogenic isoforms and uses thereof
EP2177615A1 (en) 2008-10-10 2010-04-21 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Method for a genome wide identification of expression regulatory sequences and use of genes and molecules derived thereof for the diagnosis and therapy of metabolic and/or tumorous diseases
DK3290052T3 (da) 2008-11-07 2020-02-03 Galaxy Biotech Llc Monoklonale antistoffer mod fibroblastvækstfaktorreceptor 2
WO2011025814A1 (en) 2009-08-25 2011-03-03 National Jewish Health Methods and compositions for treatment of lung injury

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070248605A1 (en) * 2003-12-19 2007-10-25 Five Prime Therapetutics, Inc. Fibroblast Growth Factor Receptors 1,2,3, and 4 as Targets for Therapeutic Intervention
WO2007134210A2 (en) * 2006-05-12 2007-11-22 Genentech, Inc. Methods and compositions for the diagnosis and treatment of cancer
WO2008118877A2 (en) * 2007-03-23 2008-10-02 The Translational Genomics Research Institute Method of diagnosing, classifying and treating endometrial cancer and precancer

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
WEI, P., et al, 2006, Hybridoma, Vol 25, No. 3, pages 115-124. *

Also Published As

Publication number Publication date
US20180094063A1 (en) 2018-04-05
HUE035700T2 (en) 2018-05-28
BRPI0917315A2 (pt) 2015-11-17
AU2009313357A1 (en) 2010-05-14
LT3290052T (lt) 2020-02-25
JP6342223B2 (ja) 2018-06-13
JP2022008996A (ja) 2022-01-14
US12679897B2 (en) 2026-07-14
JP6445496B2 (ja) 2018-12-26
EP2842573A1 (en) 2015-03-04
PT2842573T (pt) 2017-12-04
RU2011141890A (ru) 2013-04-27
US20140193899A1 (en) 2014-07-10
JP7301106B2 (ja) 2023-06-30
HRP20171640T1 (hr) 2018-01-12
EP3290052A1 (en) 2018-03-07
CA2733668C (en) 2022-08-30
US20200347141A1 (en) 2020-11-05
US20230242650A1 (en) 2023-08-03
PT2365828E (pt) 2014-12-12
DK3290052T3 (da) 2020-02-03
CN102131524B (zh) 2014-05-14
US20100196364A1 (en) 2010-08-05
ES2646168T3 (es) 2017-12-12
JP6661734B2 (ja) 2020-03-11
WO2010054265A2 (en) 2010-05-14
PL2365828T3 (pl) 2015-04-30
CA3166399C (en) 2026-02-03
RU2546254C2 (ru) 2015-04-10
EP2365828A2 (en) 2011-09-21
JP2012508184A (ja) 2012-04-05
DK2365828T3 (en) 2014-12-08
HK1249053A1 (en) 2018-10-26
ES2523740T3 (es) 2014-12-01
US8603987B2 (en) 2013-12-10
LT2842573T (lt) 2017-12-11
JP2019052165A (ja) 2019-04-04
KR20110081141A (ko) 2011-07-13
CN102131524A (zh) 2011-07-20
HRP20200090T1 (hr) 2020-04-03
EP3290052B1 (en) 2019-12-25
JP2023116746A (ja) 2023-08-22
PL3290052T3 (pl) 2020-06-29
US20120134994A1 (en) 2012-05-31
ES2770134T3 (es) 2020-06-30
EP2365828A4 (en) 2012-06-06
JP2020096615A (ja) 2020-06-25
US20190153105A1 (en) 2019-05-23
US20160362496A1 (en) 2016-12-15
EP3783024A1 (en) 2021-02-24
CA3166399A1 (en) 2010-05-14
WO2010054265A3 (en) 2010-09-16
BRPI0917315B8 (pt) 2021-05-25
KR101699432B1 (ko) 2017-01-24
MX2011000455A (es) 2011-02-25
RU2546254C9 (ru) 2015-07-10
PT3290052T (pt) 2020-02-06
JP2017019807A (ja) 2017-01-26
PL2842573T3 (pl) 2018-04-30
US9382324B2 (en) 2016-07-05
JP2025032085A (ja) 2025-03-11
US10689448B2 (en) 2020-06-23
HK1160012A1 (en) 2012-08-10
US8101723B2 (en) 2012-01-24
HK1207974A1 (en) 2016-02-19
EP2842573B1 (en) 2017-09-27
US10138301B2 (en) 2018-11-27
EP2365828B1 (en) 2014-10-15
CA2733668A1 (en) 2010-05-14
CA3287843A1 (en) 2026-03-02
NO2842573T3 (enExample) 2018-02-24
SI3290052T1 (sl) 2020-07-31
JP5627591B2 (ja) 2014-11-19
US9834609B2 (en) 2017-12-05
JP2014240385A (ja) 2014-12-25
DK2842573T3 (en) 2017-10-30
BRPI0917315B1 (pt) 2020-12-08
JP6960485B2 (ja) 2021-11-05
SI2842573T1 (en) 2018-01-31

Similar Documents

Publication Publication Date Title
US20230242650A1 (en) Monoclonal antibodies to fibroblast growth factor receptor 2
HK40045902A (en) Monoclonal antibodies to fibroblast growth factor receptor 2
HK1249053B (en) Monoclonal antibodies to fibroblast growth factor receptor 2
HK1207974B (en) Monoclonal antibodies to fibroblast growth factor receptor 2
HK1160012B (en) Monoclonal antibodies to fibroblast growth factor receptor 2

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)